These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 28860793)

  • 1. Evaluation of bleeding in patients receiving direct oral anticoagulants.
    Hellenbart EL; Faulkenberg KD; Finks SW
    Vasc Health Risk Manag; 2017; 13():325-342. PubMed ID: 28860793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct oral anticoagulants: new drugs and new concepts.
    Levy JH; Spyropoulos AC; Samama CM; Douketis J
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1333-51. PubMed ID: 25523529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulation in Pulmonary Embolism: Update in the Age of Direct Oral Anticoagulants.
    Rosovsky R; Merli G
    Tech Vasc Interv Radiol; 2017 Sep; 20(3):141-151. PubMed ID: 29029708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct oral anticoagulants (DOACs).
    Vazquez S; Rondina MT
    Vasc Med; 2015 Dec; 20(6):575-7. PubMed ID: 26285587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.
    Becattini C; Vedovati MC; Agnelli G
    Thromb Res; 2012 Mar; 129(3):392-400. PubMed ID: 22264937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens.
    Trujillo-Santos J; Di Micco P; Dentali F; Douketis J; Díaz-Peromingo JA; Núñez MJ; Cañas I; Mastroiacovo D; Saraiva de Sousa M; Monreal M;
    Thromb Haemost; 2017 Jan; 117(2):382-389. PubMed ID: 27786333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivaroxaban: an oral factor Xa inhibitor.
    Thomas TF; Ganetsky V; Spinler SA
    Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence.
    Bracey A; Shatila W; Wilson J
    Ther Adv Cardiovasc Dis; 2018 Dec; 12(12):361-380. PubMed ID: 30270775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
    Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
    Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
    Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
    Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical considerations in the use of novel oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation.
    Deitelzweig S
    Cardiovasc Ther; 2014 Apr; 32(2):74-81. PubMed ID: 24119252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New direct oral oral anticoagulants (DOACs) - indications of DOACs].
    Darius H
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2014 Mar; 49(3):182-90; quiz 191. PubMed ID: 24711238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with the new oral anticoagulants for treatment of venous thromboembolism.
    Bacchus F; Schulman S
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):513-9. PubMed ID: 25717178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of direct oral anticoagulants: insights from postmarketing studies.
    Villines TC; Peacock WF
    Am J Emerg Med; 2016 Nov; 34(11S):9-13. PubMed ID: 27697441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concerns for Bleeding in the Elderly with the Use of Direct Oral Anticoagulants.
    Min M; Sibicky S
    Consult Pharm; 2018 May; 33(5):262-267. PubMed ID: 29789047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of Direct Oral Anticoagulants: Insights from Postmarketing Studies.
    Villines TC; Peacock WF
    Am J Med; 2016 Nov; 129(11S):S41-S46. PubMed ID: 27569672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants.
    Ten Cate H; Henskens YM; Lancé MD
    Vasc Health Risk Manag; 2017; 13():457-467. PubMed ID: 29263674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
    Hernandez I; Smith KJ; Zhang Y
    Thromb Res; 2017 Feb; 150():123-130. PubMed ID: 27771008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.